CRA provided testimony on behalf of plaintiff in litigation regarding a health plan’s use of MFN clauses with hospitals. CRA identified several mechanisms by which the MFN clauses were likely to reduce competition in this matter and demonstrated that they had historically harmed competitors. CRA also analyzed whether this harm to competition was offset by the procompetitive effects of MFN clauses.
IP Literature Watch: January 2023
In this month’s IP Literature Watch we include a chapter discussing the current state of legal, economic, and policy research on standard-essential patents and...